Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Humana's Fall Creates A Rare dip Buying Opportunity: https://www.marketbeat.com/logos/articles/med_20230615101220_humanas-fall-creates-a-rare-dip-buying-opportunity.jpg
Humana's Fall Creates A Rare dip Buying Opportunity

Investors are facing one of the rarest cases in financial markets, where a deeply entrenched enterprise operating in one of the most 'defensive' sectors has left a pain trail following a 15.3%

DarioHealth is an AI-Powered Digital Therapeutics Play: https://www.marketbeat.com/logos/articles/med_20230611133641_chart-drio.jpg
DarioHealth is an AI-Powered Digital Therapeutics Play

DarioHealth Co. (NASDAQ: DRIO) is an AI-powered digital therapeutics platform and provider that adaptively personalizes monitoring and treatments for chronic diseases. The mobile app manages five

Novartis Stock Screams Value After Chinook Therapeutics Buyout: https://www.marketbeat.com/logos/articles/med_20230613065942_novartis-stock-screams-value-after-chinook-therape.jpg
Novartis Stock Screams Value After Chinook Therapeutics Buyout

Don’t be fooled by the fact that Novartis AG (NYSE:NVS) is trading near an all-time high. The Swiss pharmaceutical giant is still a good value.

That value proposition took a huge step forward on

Is the Biotech Industry (IBB) Poised For A Major Breakout?: https://www.marketbeat.com/logos/articles/med_20230612064640_is-the-biotech-industry-ibb-poised-for-a-major-bre.jpg
Is the Biotech Industry (IBB) Poised For A Major Breakout?

The iShares Biotechnology ETF (NASDAQ: IBB) has recently shown signs of potential consolidation leading to a breakout. Such price action and development should prompt investors to notice possible

Tax Software Specialist Vertex In Buy Zone After Base Breakout: https://www.marketbeat.com/logos/articles/med_20230609080552_tax-software-specialist-vertex-in-buy-zone-after-b.jpg
Tax Software Specialist Vertex In Buy Zone After Base Breakout

Tax software may not be the most glamorous business; as of today, no company in that industry has launched a virtual reality headset. However, if you’re scouting for a company with solid

Iovance Biotherapeutics Spikes on Melanoma BLA FDA Application: https://www.marketbeat.com/logos/articles/med_20230530101326_chart-iova.jpg
Iovance Biotherapeutics Spikes on Melanoma BLA FDA Application

Iovance Biotherapeutics Inc. (NASDAQ: IOVA) shares spiked over 20% on its advanced-stage melanoma treatment application to the U.S. Food and Drug Administration (FDA). The company submitted, and

A Reversal Is Brewing For Medtronic: Buying The Dip: https://www.marketbeat.com/logos/articles/med_20230525123637_chart-mdt-5252023.png
A Reversal Is Brewing For Medtronic: Buying The Dip

A reversal has been brewing for Medtronic (NYSE: MDT) and healthcare device makers all year. Increasing procedure volume, supply chain normalization, and innovation drive results and underpinning

Pfizer Has the Prescription for Higher Share Prices: https://www.marketbeat.com/logos/articles/med_20230524125944_pfizer-has-the-prescription-for-higher-share-price.jpg
Pfizer Has the Prescription for Higher Share Prices

Pfizer Inc. (NYSE: PFE) released the results of a peer review study that sent shares up more than 5%. The study evaluated the company’s GLP-1 receptor agonist, danuglipron. The compound aimed to

Microbot Medical spikes 150% on its Endovascular Surgical Robot: https://www.marketbeat.com/logos/articles/med_20230523111957_chart-mbot.jpg
Microbot Medical spikes 150% on its Endovascular Surgical Robot

Microbot Medical Inc. (NASDAQ: MBOT) stock spiked more than 150% on a massive 194 million share volume on a successful pre-clinical animal study for its LIBERTY surgical robotic system. Shares hit

Neurimmune: Promising Phase 1 Results for Antibody NI006 in ATTR Cardiomyopathy Published in the New England Journal of Medicine: https://www.irw-press.at/prcom/images/messages/2023/70633/Accesswire-Neurimmune_220523.001.jpeg
Neurimmune: Promising Phase 1 Results for Antibody NI006 in ATTR Cardiomyopathy Published in the New England Journal of Medicine

Results also presented during late-breaking session at ESC Heart Failure congress 2023

 

ZURICH, SWITZERLAND / ACCESSWIRE / May 20, 2023 / Neurimmune announced today that primary results of

Is Pfizer's Seagen Deal In Jeopardy Amid Antitrust Scrutiny?: https://www.marketbeat.com/logos/articles/med_20230518141428_is-pfizers-seagen-deal-in-jeopardy-amid-antitrust.jpg
Is Pfizer's Seagen Deal In Jeopardy Amid Antitrust Scrutiny?

Pfizer Inc. (NYSE: PFE) continued its downward trajectory on May 17, following news that the Federal Trade Commission is seeking to block Amgen Inc.’s (NASDAQ: AMGN) planned acquisition of Horizon

Zoetis Declares New Dividend, Hinting At Undervaluation: https://www.marketbeat.com/logos/articles/med_20230518102050_zoetis-declares-new-dividend-hinting-at-undervalua.jpg
Zoetis Declares New Dividend, Hinting At Undervaluation

Zoetis (NYSE: ZTS) shareholders may have a new reference point to be excited about, even after witnessing some favorable developments through the company's first quarter 2023 announcements. Even

Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings: https://www.marketbeat.com/logos/articles/med_20230518072749_vertex-pharmaceuticals-hits-record-high-on-strong.jpg
Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), maker of Cystic fibrosis drugs, rallied to a record high on May 2 after a better-than-expected first-quarter earnings report. 

Net income of $3.05 a

How to Invest in Telehealth and Telemedicine Stocks: https://www.marketbeat.com/logos/articles/med_20230517114005_telemedicine-stocks.png
How to Invest in Telehealth and Telemedicine Stocks

Coming into prominence during the COVID-19 pandemic, telemedicine stocks saw increases in price and profitability in the past five years. As relaxed government regulations allowed service

The Turnaround for Weight Watchers is Taking Shape: https://www.marketbeat.com/logos/articles/med_20230514180546_charty-ww.jpg
The Turnaround for Weight Watchers is Taking Shape

Weight management meals and services provider WW International Inc. (NYSE: WW) stock made a 52-week high of $10.02 after its Q1 2023 earnings release. Shares collapsed (26%) as Artal Group S.A

Sarepta Soars 31% As FDA Panel Backs Muscular Dystrophy Therapy: https://www.marketbeat.com/logos/articles/med_20230516050346_sarepta-soars-31-as-fda-panel-backs-muscular-dystr.jpg
Sarepta Soars 31% As FDA Panel Backs Muscular Dystrophy Therapy

Sarepta Therapeutics Inc. (NASDAQ: SRPT) jumped nearly 31% on May 15, after a Food and Drug Administration committee gave a thumbs up to the company’s experimental gene therapy to treat Duchenne

UnitedHealth Group is an AI Stock That Isn't Beating Expectations: https://www.marketbeat.com/logos/articles/med_20230515071148_unitedhealth-group-is-an-ai-stock-that-isnt-beatin.jpg
UnitedHealth Group is an AI Stock That Isn't Beating Expectations

UnitedHealth Group Inc. (NYSE: UNH) is down 7.2% in 2023. The health maintenance organization (HMO) sector in general is lagging the market. So, investors may simply be taking a pause on a stock

Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales: https://www.marketbeat.com/logos/articles/med_20230504211613_regeneron-beats-q1-views-but-stock-drops-on-weak-e.jpg
Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) gapped down more than 6% on May 4, despite reporting better-than-expected first-quarter earnings and revenue.

Net income tumbled by 12% to $10.09 a

Will Forced Divesture Of Grail Boost Illumina Shareholder Value?: https://www.marketbeat.com/logos/articles/med_20230502151412_will-forced-divesture-of-grail-boost-illumina-shar.jpg
Will Forced Divesture Of Grail Boost Illumina Shareholder Value?

The phrase, “I’m from the government and I’m here to help” has a well-deserved reputation as a terrifying phrase, but for medical researcher Illumina Inc. (NASDAQ: ILMN), which specializes in DNA

Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding: https://www.marketbeat.com/logos/articles/med_20230502115431_chart-canf.jpg
Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding

Can-Fite BioPharma Ltd. (NYSEAMERICAN: CANF) is an Israel-based biotechnology firm that develops small-molecule therapeutic treatments for cancers, inflammatory diseases and sexual dysfunction. It

High-Yield Pfizer Falls Off The COVID Cliff, And Survives: https://www.marketbeat.com/logos/articles/med_20230502093017_chart-pfe-522023.png
High-Yield Pfizer Falls Off The COVID Cliff, And Survives

Pfizer (NYSE: PFE) was expected to post a significant decline in revenue and earnings because of the slowing COVID business, and it did. However, the takeaway from the report is that business is

Can Butterfly Network Spread its Wings in 2023?: https://www.marketbeat.com/logos/articles/med_20230430132321_chart-blfy.jpg
Can Butterfly Network Spread its Wings in 2023?

Butterfly Network Inc. (NYSE: BFLY) is a medical imaging solutions company that makes point-of-demand portable ultrasound devices to bring medical imaging to healthcare providers at a deep

Virios Therapeutics Up 75% on Fibromyalgia Phase 3 Proposal: https://www.marketbeat.com/logos/articles/med_20230425102047_chart-viri.jpg
Virios Therapeutics Up 75% on Fibromyalgia Phase 3 Proposal

Virios Therapeutics Inc. (NASDAQ: VIRI) is a developmental-stage biotechnology company specializing in novel antiviral therapies for treating fibromyalgia and other abnormal immune

Why Legend Biotech Stock Is Having Its Best Month Yet: https://www.marketbeat.com/logos/articles/med_20230424135734_why-legend-biotech-stock-is-having-its-best-month.jpg
Why Legend Biotech Stock Is Having Its Best Month Yet

Legend Biotech Corporation (NASDAQ: LEGN) is among the many healthcare names vying for a breakthrough in cancer treatment. Last week, the New Jersey-based company had just that.

On April 19th, a